202 results on '"Prey, Sorilla"'
Search Results
2. Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study
3. Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas
4. Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors
5. Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade
6. Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study
7. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events
8. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
9. Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.
10. Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.
11. Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy
12. Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)
13. Clinical Impact of Proton Pump Inhibitors and Other Co-medications on Advanced Melanoma Patients Treated With BRAF/MEK inhibitors.
14. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
15. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up
16. Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient
17. Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma
18. Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma
19. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients
20. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo
21. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
22. Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod
23. Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
24. Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey
25. Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up
26. Vitiligo-like lesions in patients receiving anti–programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo
27. ESDR470 - Infantile hemangioma telocytes and noradrenaline are the prerequisite for response to propranolol
28. Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.
29. Abstract CT109: Radiomic features in tumor assessment, preliminary results from a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with anti PD1 refractory melanoma
30. Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study
31. Abstract CT107: Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma
32. Is Infantile Hemangioma a Neuroendocrine Tumor?
33. Safety of Propranolol Therapy for Severe Infantile Hemangioma
34. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma
35. Rôle critique de l’aquaporine-1 et des télocytes dans la réponse de l’hémangiome infantile au propranolol
36. Récidives sous traitement adjuvant dans le mélanome : caractéristiques et prise en charge
37. Caractéristiques cliniques des patients atteints de mélanome avancé développant un vitiligo sous anti-PD-1
38. 961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy
39. Real-life use of trametinib after immunotherapy failure in BRAFwild-type advanced melanoma
40. A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma
41. Brief Communication: Lambert-Eaton Myasthenic Paraneoplastic Syndrome Associated With Merkel Cell Carcinoma Successfully Treated by Immune Checkpoint Inhibitors: 2 Cases.
42. Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma
43. Mast cells as possible targets of propranolol therapy: an immunohistological study of beta-adrenergic receptors in infantile haemangiomas
44. Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
45. IFAG and Childhood Rosacea: A Possible Link?
46. Development and validation of the K-VSCOR for scoring Koebner's phenomenon in vitiligo/non-segmental vitiligo
47. Halo Nevi Association in Nonsegmental Vitiligo Affects Age at Onset and Depigmentation Pattern
48. Congenital haemangiomas: a single-centre retrospective review
49. Association of Anti–Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma
50. Infantile Acne: A Retrospective Study of 16 Cases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.